INM-901 — FDA meeting
Q3 2026
Conduct a pre-IND meeting with the U.S. Food and Drug Administration in the third quarter of 2026.Source filing
INM biotech catalysts & pipeline
INMED PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
INM-089 — FDA meeting
Q4 2026
Planning for a pre-IND meeting with the FDA in Q4 2026.Source filing
INM-901 — IND submission
2027
• Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027.Source filing
MT-002 — Topline data
2027
These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027.Source filing
MT-002 — IND submission
1Q 2027
First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectivelySource filing
MT-001 — Topline data
2028
These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027.Source filing
MT-002 — Interim data
into 2029
The financing, based on current plans, extends Mentari's cash runway into 2029 and through phase 2a readout on each of the two PACAP-targeted lead programs, including MT-002.Source filing